Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 drug-drug interaction study of IMU-838 with curcumin and rosuvastatin
NL-OMON59626Phase 1Completed
- Sponsor
- Immunic Therapeutics
- Start
- Jan 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vidofludimus calcium, curcumin and rosuvastatin in multiple sclerosis (MS), sponsored by Immunic Therapeutics. Started Jan 2026; status: completed.
02
Drugs
vidofludimus calciumcurcuminrosuvastatin
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON59626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59626.